{
  "docId": "019de071-41d7-735b-bdce-76898f0847d2",
  "docSlug": "eaafde7daeccaea38d88b7264ade91c5",
  "documentTitle": "Erasca | IPO Presentation Deck | 46 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 44,
  "pageCount": 46,
  "prevPage": 43,
  "nextPage": 45,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 100,
  "notes": "The slide uses a heatmap-style table with overlays to indicate specific clinical trial programs (HERKULES-1/2/3/4, FLAGSHP-1) mapped against patient population data.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de071-41d7-735b-bdce-76898f0847d2/44",
  "deckHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2",
  "deckJsonHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2.json",
  "deckAnchorHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2#slide-44",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.15,
        "y": 0.15
      },
      "kind": "callout",
      "text": "HERKULES-2 007/MAPKlamp + osimertinib",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12a896f5-3a06-4993-902f-ed68b36037a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.75,
        "y": 0.35
      },
      "kind": "callout",
      "text": "HERKULES-1 & FLAGSHP-1 MAPKlamp: ERAS-007 + ERAS-601 (tissue agnostic)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3bd68937-73ef-4124-968e-d82df216121e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.45,
        "y": 0.25
      },
      "kind": "callout",
      "text": "HERKULES-3 007/MAPKlamp + KRAS G12Ci(s)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "acb899e3-afe0-4574-959a-62f332be488e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "Source: SEER database (2020), ECIS database (2020), GLOBOCAN database (2020), The AACR Project GENIE Consortium version 8.1 (2020), TCGA Research Network...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6bcb56ab-521f-4917-8ed5-20d9db9be2ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.5,
        "y": 0.85
      },
      "kind": "legend",
      "text": "Blue ocean opportunities / Red ocean opportunities",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9fcfe536-d195-426b-a6cf-804e2a6dc67b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.94,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "table",
      "text": "Table showing Alterations vs Indications (NSCLC, CRC, Melanoma, PDAC, etc.) with patient counts.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f0c5747d-5467-4171-acb5-7434babf7720",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.94,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Erasca's tissue specific and tissue agnostic trials target multiple indications",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a6194d5-39c7-4c81-9829-5eca3c6459eb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Market Segmentation Pyramid",
      "slug": "market-segmentation-pyramid",
      "agent": null,
      "layer": "slide",
      "matchId": "4c82e5c6-a926-48a9-9b4d-3446d9226088",
      "evidence": "Table showing Alterations vs Indications (NSCLC, CRC, Melanoma, PDAC, etc.) with patient counts.",
      "confidence": 0.6
    }
  ],
  "frameworks": [
    {
      "name": "Blue Ocean Strategy",
      "slug": null,
      "matchId": "6eabbaf5-2bf8-4633-a548-21e79d388404",
      "evidence": "Explicit mention of 'Blue ocean opportunities' and 'Red ocean opportunities' in legend.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}